Peptide LibraryBAM15
Also known as: N5,N6-bis(2-fluorophenyl)[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine
BAM15 (also called N5,N6-bis(2-fluorophenyl)[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine) is a small molecule in the Mitochondrial Uncoupler (Protonophore) class. Increases inner-mitochondrial-membrane proton leak, uncoupling oxidative phosphorylation from ATP synthesis and raising energy expenditure in cells and rodents without the classic DNP-like off-target toxicity profile in published models.
For research use only.
Key Facts
- CAS
- 210302-17-3
- Molecular Weight (MW)
- 340.29 g/mol
- Half-life
- Not established (limited public PK; primarily preclinical/in vitro characterization)
- FDA status
- Not Approved
- Evidence level
- Insufficient Evidence
- Human dose established
- No
- Administration Route
- Not established in humans
- Frequency
- Not established in humans
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
- Targets
- Mitochondrial inner membrane
Vendor price snapshot
Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected in Nov 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 9
- Listed offers
- 12
- Median price per mg (capsules)
- $0.090/mg
- Typical $0.070–$0.098/mg
By form
Each form is priced on its own: a price per mg doesn't make a spray or a capsule equivalent to a vial.
Research summary
Mitochondrial protonophore uncoupler used in metabolic research to increase energy expenditure independently of beta-oxidation stimulation. Not FDA-approved; not a peptide.
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trialsNone in reviewed sources
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studies3 reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's BAM15 profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
BAM15 dosage: no established human dose
BAM15 has no established human dosage. It is a small molecule, not a peptide: a mitochondrial uncoupler that makes the inner mitochondrial membrane leak protons. No trial of it is registered on ClinicalTrials.gov and no human study is indexed in PubMed. The published work is in cells and in mice, where it was most often mixed into the animals' food, for example at 0.1% by weight of a high-fat diet.
No established human dosage.
Human clinical evidence: None identified.
Preclinical research: BAM15 is a synthetic oxadiazolopyrazine, a small molecule rather than a peptide, and it is studied as a mitochondrial uncoupler for obesity, fatty liver disease, sepsis and cancer models. All published dosing is in cells (concentrations in the medium) and in rodents (a percentage of the diet or weight-based injections). Neither converts into a human dose, and no human study or registered trial of BAM15 exists, so no dose, route or interval is established. Published work on this class also notes that older uncouplers such as 2,4-dinitrophenol have a narrow margin between an active and a harmful amount.
Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.
| Human dosing established | No |
|---|---|
| Route | Not established in humans |
| Evidence level | Insufficient Evidence |
| Last reviewed | 2026-11-07 |
Preclinical and analog research
Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Preclinical — BAM15 in diet-induced obese mice (2020)Preclinical · Animal study | Mice on a diet that causes obesity | Not stated in the indexed abstract; the authors report it is active when given by mouth | Oral | — | — | More nutrient oxidation and less body fat without a change in food intake, lean mass or body temperature, plus better insulin sensitivity in clamp studies | Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice. Nat Commun. 2020. |
| Preclinical — BAM15 mixed into a high-fat diet in mice, 10 weeks (2022)Preclinical · Animal study | Mice with obesity-related muscle loss | 0.1% by weight of the diet (non-human) | In the diet | — | 10 weeks | Lower body weight, more muscle mass and grip strength, and activation of mitochondrial quality-control pathways | Mitochondrial uncoupling attenuates sarcopenic obesity by enhancing skeletal muscle mitophagy and quality control. J Cachexia Sarcopenia Muscle. 2022. |
| Preclinical — the study that first identified BAM15, in cells and mice (2014)Preclinical · Cell and animal study | Cultured cells; mice with acute kidney ischaemia-reperfusion injury | Not stated in the indexed abstract; the protective effect in mice is described as dose-dependent | Not stated in the indexed abstract | — | — | Raised the maximum rate of mitochondrial respiration with less cell toxicity than the older uncoupler FCCP, and protected mice from kidney injury | Identification of a novel mitochondrial uncoupler that does not depolarize the plasma membrane. Mol Metab. 2014. |
Where sources disagree
- A ClinicalTrials.gov search for "BAM15" returns a COVID-19 antibody study (NCT04634409) in which "BAM" abbreviates bamlanivimab. That trial has nothing to do with this compound, and no trial of BAM15 itself is registered.
- BAM15 is sold as capsules, tablets and liquids rather than as a powder for injection, so the reconstitution arithmetic used for peptide vials does not apply to it.
- Several of the mouse papers are authored by people with a declared financial interest in developing mitochondrial uncouplers, which the papers disclose.
- A percentage of an animal's diet is not a dose for a person: it depends on how much the animal eats and on its body size.
Handling & administration
- Reconstitution Guide
- Typically dissolved in DMSO for lab use; follow COA/MSDS and lab SOPs
- Concentration Example
- Stock solutions commonly prepared for in vitro assays (vendor guidance varies)
- Expected Onset
- Acute mitochondrial respiration effects in vitro
Sequence & molecular data
| Amino acid sequence | N/A (small-molecule mitochondrial protonophore; not a peptide) |
|---|---|
| Molecular formula | C16H10F2N6O |
| Molecular weight | 340.29 g/mol |
| CAS number | 210302-17-3 |
| Half-life | Not established (limited public PK; primarily preclinical/in vitro characterization) |
| Appearance | Yellow to orange solid/powder (typical small-molecule appearance; vendor-dependent) |
| Formulation | Lyophilized Powder |
| PubChem CID | 565708 |
| ChEMBL | CHEMBL3627755 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Increases inner-mitochondrial-membrane proton leak, uncoupling oxidative phosphorylation from ATP synthesis and raising energy expenditure in cells and rodents without the classic DNP-like off-target toxicity profile in published models.
Origin
Synthetic oxadiazolopyrazine small molecule.
Targets
Studies
- Targeting Mitochondrial Dysfunction to Prevent Endothelial Dysfunction and Atherosclerosis in Diabetes: Focus on the Novel Uncoupler BAM15
- BAM15 as a mitochondrial uncoupler: a promising therapeutic agent for diverse diseases
- BAM15 improves oocyte quality against obesity via PPARγ-dependent mitochondrial function
- BAM15 inhibits endothelial pyroptosis via the NLRP3/ASC/caspase-1 pathway to alleviate atherosclerosis
- Beneficial effects of MGL-3196 and BAM15 combination in a mouse model of fatty liver disease
Research statistics
60 PubMed publications · 0.0% human clinical research · 0 registered trials
Counts of published research through 2026-11-01, not evidence that it works. Publications by year, study types and trials · How publications are counted
Regulatory & research status
BAM15 is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
How FDA approval, compounding and research-only status differ
Benefits
BAM15 side effects
BAM15 has no controlled human safety data. The effects below are reported, not established, and absence from the list is not evidence of safety.
Side Effects
- Hyperthermia risk class-effect of uncouplers
- No approved human dose
Storage & stability
This compound is not supplied as a powder to be mixed, so the freeze-dried powder and reconstitution handling described for research peptides does not apply. Storage conditions are product-specific: follow the label or packaging of the product itself.
BAM15: frequently asked questions
What is BAM15?
Mitochondrial protonophore uncoupler used in metabolic research to increase energy expenditure independently of beta-oxidation stimulation. Not FDA-approved; not a peptide.
How does BAM15 work?
Increases inner-mitochondrial-membrane proton leak, uncoupling oxidative phosphorylation from ATP synthesis and raising energy expenditure in cells and rodents without the classic DNP-like off-target toxicity profile in published models.
Is BAM15 FDA approved?
No. BAM15 is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of BAM15?
Reported half-life for BAM15 is Not established (limited public PK; primarily preclinical/in vitro characterization). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
What is the amino acid sequence of BAM15?
BAM15 has the sequence N/A (small-molecule mitochondrial protonophore; not a peptide), giving a chain of 2 amino acids. Its molecular formula is C16H10F2N6O.
What peptides are similar to BAM15?
Compounds most often compared with BAM15 include 5-Amino-1MQ, SLU-PP-332, AICAR and Tesofensine. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- PubChem BAM15External reference
- Targeting Mitochondrial Dysfunction to Prevent Endothelial Dysfunction and Atherosclerosis in Diabetes: Focus on the Novel Uncoupler BAM15 — Int J Mol Sci, 2025External reference
- BAM15 as a mitochondrial uncoupler: a promising therapeutic agent for diverse diseases — Front Endocrinol (Lausanne), 2023External reference
- BAM15 improves oocyte quality against obesity via PPARγ-dependent mitochondrial function — Protein Cell, 2026External reference
- BAM15 inhibits endothelial pyroptosis via the NLRP3/ASC/caspase-1 pathway to alleviate atherosclerosis — Atherosclerosis, 2025External reference
- Beneficial effects of MGL-3196 and BAM15 combination in a mouse model of fatty liver disease — Acta Physiol (Oxf), 2024External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 2
This BAM15 profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track BAM15 research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →